- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic severe atopic dermatitis
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 650KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 120KB)
Dupilumab – July 2023
Dupilumab: Injection 200 mg in 1.14 mL single dose pre filled syringe, Injection 300 mg in 2 mL single dose pre filled syringe; Dupixent®
Last updated
27 October 2023